Candesartan improves insulin resistance induced by high-fat diet in rats

National Medical Journal of China

Volumn 88, Issue 38, 2008, Pages 2695-2699

  Yan, Wen Hua ^a   Dou, Jing Tao ^a   Pan, Chang Yu ^a   Chen, Kang ^a   Wang, Xue Min ^a   Ma, Fang Ling ^a   Yang, Guo Qing ^a   Wang, Xian Ling ^a   Mu, Yi Ming ^a   Lu, Ju Ming ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

Angiotensin II type 1 receptor blockers; High fat diet; Insulin resistance

Indexed keywords

CANDESARTAN; CHOLESTEROL; FATTY ACID; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; TRIACYLGLYCEROL;

ABDOMINAL AORTA; ADIPOSE TISSUE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIET RESTRICTION; DRUG MECHANISM; EPIDIDYMIS; FATTY ACID BLOOD LEVEL; GLUCOSE BLOOD LEVEL; GLUCOSE CLAMP TECHNIQUE; IMMUNOHISTOCHEMISTRY; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPID DIET; LIVER PARENCHYMA; LIVER WEIGHT; MALE; NONHUMAN; ORAL GLUCOSE TOLERANCE TEST; RADIOIMMUNOASSAY; RAT; TRIACYLGLYCEROL BLOOD LEVEL; WISTAR RAT;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; BENZIMIDAZOLES; DIETARY FATS; INSULIN; INSULIN RESISTANCE; MALE; RATS; RATS, WISTAR; TETRAZOLES;

EID: 56349131421     PISSN: 03762491     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Chinese source.
2. Abuissa H, Jones PG, Marso SP, et al. Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for prevention of type 2 diabetes: a meta-analysis of randomized clinical trials. J Am Coll Cardiol, 2005, 46:821-826.
3. Benson SC, Pershadsingh HA, Ho CI, et al. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity. Hypertension, 2004, 43:993-1002.
4. Cheung A, Bryer-Ash M. Modified method for the performance of glucose insulin clamp studies in conscious rats. J Pharmacol Toxicol Methods,1994, 31:215-220.
5. Rave K, Flesch S, Kühn-Velten WN, et al. Enhancement of blood glucose lowering effect of a sulfonylurea when coadministered with an ACE inhibitor: results of a glucose-clamp study. Diabetes Metab Res Rev, 2005, 21:459-464.
6. Goossens GH, McQuaid SE, Dennis AL, et al. Angiotensin II: a major regulator of subcutaneous adipose tissue blood flow in humans. J Physiol,2006, 571:451-460.
7. Velloso LA, Folli F, Perego L, et al. The multi-faceted cross-talk between the insulin and angiotensin II signaling systems. Diabetes Metab Res Rev, 2006, 22:98-107.
8. Janke J, Engeli S, Gorzelniak K, et al. Mature adipocytes inhibit in vitro differentiation of human preadipocytes via angiotensin type 1 receptors. Diabetes,2002, 51:1699-1707.
9. Blendea MC, Jacobs D, Stump CS, et al. Abrogation of oxidative stress improves insulin sensitivity in the Ren-2 rat model of tissue angiotensin II overexpression. Am J Physiol Endocrinol Metab, 2005, 288:E353-E359.
10. Sola S, Mir MQ, Cheema FA, et al. Irbesartan and lipoic acid improve endothelial function and reduce markers of inflammation in the metabolic syndrome: results of the Irbesartan and Lipoic Acid in Endothelial Dysfunction (ISLAND) study. Circulation, 2005, 111:343-348.
11. Kamin D, Hadigan C, Lehrke M, et al. Resistin levels in human immunodeficiency virus-infected patients with lipoatrophy decrease in response to rosiglitazone. J Clin Endocrinol Metab, 2005, 90: 3423-3426.
12. Tham DM, Martin-McNulty B, Wang YX, et al. Angiotensin II is associated with activation of NF-kappaB-mediated genes and downregulation of PPARs. Physiol Genomics,2002, 11:21-30.
13. Arenas IA, Xu Y, Lopez-Jaramillo P. Angiotensin II-induced MMP-2 release from endothelial cells is mediated by TNF-alpha. Am J Physiol Cell Physiol, 2004, 286:C779-C784.
14. Tuck ML. Angiotensin receptor blocking agents and the peroxisome proliferator activated receptor gamma system. Curr Hypertens Rep, 2005, 7:240-243.
15. Benson SC, Pershadsingh HA, Ho CI, et al. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity. Hypertension, 2004, 43:993-1002.
16. Schupp M, Janke J, Clasen R, et al. Angiotensin type 1 receptor blockers induce peroxisome proliferator activated receptor gamma activity. Circulation, 2004,109:2054-2057.
17. Chinese source.
18. Morsing P, Adler G, Brandt-Eliasson U, et al. Mechanistic differences of various AT1-receptor blockers in isolated vessels of different origin. Hypertension, 1999, 33:1406-1413.